Palantir UK boss urges government to keep £330m NHS data contract

TL;DR: Louis Mosley, Palantir’s UK executive vice-chair, has warned ministers against exiting the company’s £330m NHS Federated Data Platform contract. Government officials are reportedly exploring a break clause that becomes active next year, amid growing political and public unease about the US data firm’s role in British public services.

Palantir’s most senior UK figure has publicly pushed back against what he called “ideologically motivated campaigners” seeking to end the company’s role in NHS data infrastructure. The intervention comes as government ministers have sought legal advice on triggering a break clause in the Federated Data Platform contract.

A contract under growing scrutiny

The FDP is an AI-enabled system designed to connect fragmented health data across the NHS. Mosley told the Times the platform was forecast to deliver £150m in benefits by the end of the decade, representing “a £5 return for every pound spent.”

Government officials have argued it would be technically feasible to transfer the platform’s operation to another provider, according to the Financial Times. The break clause becomes available next year.

Concerns about Palantir extend beyond the political left. Labour MP Clive Lewis said the company had begun coming up on the doorstep with voters in his Norwich South constituency, reflecting wider public anxiety about AI and data control.

The political calculation

Health Secretary Wes Streeting has acknowledged the unease, describing Palantir co-founder Peter Thiel’s political views as “well off to the right of even Kemi Badenoch’s Conservative party.” He stressed, however, that Palantir does not access patient data directly.

The number of NHS organisations using Palantir technology has grown from 118 to 151 since June, though this remains well short of the 240 target for year-end. The BMA, representing NHS doctors, has maintained its opposition to Palantir’s involvement in patient care delivery.

Looking forward

The debate over Palantir’s NHS presence sits at the intersection of several live concerns for UK policymakers: dependence on US technology firms, data sovereignty, and public trust in AI-driven healthcare systems. With the break clause approaching, the government faces a decision that will signal how seriously it takes those concerns — and whether value-for-money arguments can outweigh growing political risk.